{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-274082","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.409714+00:00","generated_at":"2026-06-08T07:17:18.230688+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Phathom Q3 net loss $43.2M; VOQUEZNA FDA approved for Erosive GERD; Dec launch","bullets":["Net loss $43.2M in Q3 2023 vs $51.1M in Q3 2022; includes $6.1M stock-based compensation.","Cash $213.7M at Sep 30; $175M from revenue interest financing plus $100M Hercules loan available.","FDA approved VOQUEZNA (vonoprazan) for Erosive GERD in Nov 2023; launch expected Dec 2023.","NDA submitted for vonoprazan as daily Non-Erosive GERD treatment in Sep 2023; FDA action Q3 2024.","Phase 3 As Needed NERD trial to start in 2024; cash expected to fund ops through end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-274082","json":"https://secwatch.observer/filing/0001193125-23-274082.json","markdown":"https://secwatch.observer/filing/0001193125-23-274082.md","text":"https://secwatch.observer/filing/0001193125-23-274082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523274082/0001193125-23-274082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523274082/d593359d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:17:18.230688+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fce8d7114ca340e9d2102a4235067eab3d3f6eb8","claim":"Phathom Pharmaceuticals, Inc. reported the third quarter of 2023 results: net income $43.2 million.","evidence_excerpt":"Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the third quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523274082/0001193125-23-274082-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Net income","value":"$43.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}